AMBALAL SARABHAI ENT L
Latest filings
Next results: Thu, 5 Nov · Financial Results- Board to approve September 2026 quarterly and half-year results · Results
- Reg 74(5) compliance certificate filed with BSE for quarter ended Sept 2026 · Compliance
- Trading window closed from Oct 1 till 48 hours after Q2 results · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Runs two business segments - Pharmaceuticals and Electronics - through group companies, generating consolidated revenue of Rs 202.27 crore in FY26. The Pharmaceuticals business is operated through Asence Pharma and the Electronics business through Systronics India, with Synbiotics as an additional group entity; both segments reported positive EBIT in FY26. Electronics was the faster-growing of the two in Q3 FY26, growing about 34% year-on-year while Pharmaceuticals stayed largely flat. On the cost side, raw materials are only 9.5% of revenue while employees absorb 16.1% and other operating expenses 19.2%, indicating limited direct commodity exposure. Depreciation of 1.9% and capex of 2.1% of revenue point to a low capital-intensity operating model.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from AMBALAL SARABHAI ENT L's filed financials and exchange disclosures
What does AMBALAL SARABHAI ENT L do?
AMBALAL SARABHAI ENT L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AMBALALSA.
Is AMBALAL SARABHAI ENT L profitable?
Yes. Over the trailing twelve months AMBALAL SARABHAI ENT L reported a net profit of ₹18 Cr on revenue of ₹202 Cr.
Does AMBALAL SARABHAI ENT L pay a dividend?
Not in the latest reported year — AMBALAL SARABHAI ENT L's dividend payout for FY26 was nil.
Is AMBALAL SARABHAI ENT L debt-free?
No. It reported borrowings of ₹52 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹45 Cr after cash. Debt stands at 0.33× equity. That is higher than 71% of its 166 Pharmaceuticals peers.
Is AMBALAL SARABHAI ENT L expensive compared with its peers?
On trailing P/E, AMBALAL SARABHAI ENT L ranks 32 of 158 in Pharmaceuticals — cheaper than 80% of them, against an industry median of 29.7×. This is a position, not a valuation judgement.
How much does the AMBALAL SARABHAI ENT L share price move in a day?
On a typical session AMBALAL SARABHAI ENT L moves 2.04% — that is the median absolute close-to-close move across its last 131 trading days. MarketPing measures each filing's price reaction against it.
When are AMBALAL SARABHAI ENT L's next results?
Financial Results on Thu, 5 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track AMBALAL SARABHAI ENT L's announcements?
Every NSE and BSE filing by AMBALAL SARABHAI ENT L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.